Summary
This American Association for the Study of Liver Diseases practice guideline provides evidence-based clinical recommendations for the assessment and management of nonalcoholic fatty liver disease. The guidance addresses identification of patients at risk of advanced fibrosis and cirrhosis, evaluation of disease severity through contemporary diagnostic approaches, and both pharmacological and non-pharmacological management strategies. The document likely emphasises lifestyle modification including dietary and metabolic approaches as foundational management, with guidance on patient selection for emerging pharmacotherapies.
Regional applicability
UK clinicians and hepatologists can adapt these evidence-based recommendations to the NHS context, though implementation may depend on local availability of diagnostic tools and pharmacological agents. The emphasis on lifestyle modification and metabolic risk factor management aligns with UK public health priorities around obesity and metabolic disease prevention.
Key measures
Diagnostic criteria for NAFLD, fibrosis staging, markers of disease severity, treatment efficacy outcomes
Outcomes reported
The guideline synthesises evidence on clinical assessment methods, patient stratification by fibrosis risk, and management approaches for nonalcoholic fatty liver disease. It evaluates both diagnostic strategies and treatment options including lifestyle modification and pharmacological interventions.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.